UPDATE 1-Madrigal, China's Suzhou Ribo sign license deal for liver‑disease programs

+1.67% Pre

Madrigal Pharmaceuticals, Inc.

MDGL

438.73

+1.67%

0.00% Pre

Adds details throughout

Feb 11 (Reuters) - Madrigal Pharmaceuticals MDGL.O said on Wednesday it has signed an exclusive global license agreement with China-based Suzhou Ribo Life Science 6938.HK and its unit Ribocure for six preclinical small interfering RNA programs to treat a type of liver disease.

Suzhou Ribo has granted Madrigal exclusive global rights to develop, manufacture and commercialize the six siRNA compounds.

The Chinese biotech will receive an upfront payment of $60 million, and total payments across the programs could reach up to $4.4 billion if certain development, regulatory and commercial milestones are met.

Suzhou Ribo will also receive royalties on future net sales.

The agreement is for the development of therapies to treat metabolic dysfunction-associated steatohepatitis.

MASH is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.